Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | GABRE | P78334 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160291 | 1.00 | TSHR (0.50) | TSHRLMNAPLGPLATGABRP | |
| SCHEMBL482042 | 1.00 | TSHR (0.50) | TSHRLMNAPLGPLATGABRP | |
| SCHEMBL28889340 | 1.00 | TSHR (0.50) | TSHRLMNAPLGPLATGABRP | |
| Ammonia Solution, Strong SCHEMBL27806834 | 0.97 | LMNA (0.48) | TSHRLMNAPLGPLATGABRP | |
| SCHEMBL11415493 | 0.92 | LMNA (0.44) | TSHRLMNAPLGPLATGABRP | |
| SCHEMBL28721496 | 0.90 | TSHR (0.58) | TSHRLMNAPLGPLATGABRP | |
| SCHEMBL10949703 | 0.87 | TSHR (0.48) | TSHRLMNAPLGPLATGABRP | |
| SCHEMBL10956192 | 0.87 | TSHR (0.48) | TSHRLMNAPLGPLATGABRP | |
| SCHEMBL10959207 | 0.87 | TSHR (0.48) | TSHRLMNAPLGPLATGABRP | |
| SCHEMBL10956388 | 0.87 | TSHR (0.48) | TSHRLMNAPLGPLATGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117147721-A | Method for distinguishing fermented soybeans from fermented soybeans | 中南林业科技大学 | 2023-12-01 | — | — | CN | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| US-10435383-B2 | C-glycoside derivatives | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2019-10-08 | — | — | US | claimed |
| US-20180118703-A1 | C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2018-05-03 | — | — | US | claimed |
| WO-2016151989-A1 | C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2016-09-29 | — | — | WO | claimed |
| US-20090312327-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | claimed |
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | disclosed |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| EP-4103559-B1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4688782-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | Danatlas Pharmaceuticals Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-6410541-B2 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES ADMINISTERED AS ANTITUMOR AGENTS | SCHERING CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-20010007870-A1 | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents | REMISZEWSKI STACY W (US) | 2001-07-12 | — | — | US | disclosed |
| US-6211193-B1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES; ANTITUMOR AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2001-04-03 | — | — | US | disclosed |
| CN-1286690-A | Compounds useful for inhibition of farnesyl protein transferase | SCHERING CORP (US) | 2001-03-07 | — | — | CN | disclosed |
| EP-0993459-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998057955-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| US-5411989-A | Cardiovascular disorders | BOEHRINGER MANNHEIM, GMBH (DE) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435383-B2 | C-glycoside derivatives | UGCG, FUT6, FUT5 | TSHR 3975/4885LMNA 3491/4885PLG 2377/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | TSHR 3099/4885LMNA 952/4885PLG 4684/4885 |
| US-20090312327-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | TACR2, PRLHR, AVPR2 | TSHR 64/4885LMNA 3612/4885PLG 1942/4885 |
| US-20010007870-A1 | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents | HCCS, FNTB, CBR1 | TSHR 2691/4885LMNA 3055/4885PLG 4810/4885 |
| US-20180118703-A1 | C-GLYCOSIDE DERIVATIVES | UGCG, FUT6, FUT5 | TSHR 3975/4885LMNA 3491/4885PLG 2377/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | TSHR 2229/4885LMNA 3574/4885PLG 3875/4885 |
| US-20260049088-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | SRD5A2, CBR1, SRD5A1 | TSHR 255/4885LMNA 1297/4885PLG 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.